[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335755-105":59,"doc-detail-335755-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","association-of-tp53-mutation-status-and-sex-with-clinical-outcome-in-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors-a-retrospective-cohort-study","Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors - A Retrospective Cohort Study","","Retrospective cohort evidence evaluates whether TP53 mutation status relates to sex differences in response to immune checkpoint inhibitors in metastatic non-small cell lung cancer. Clinical data from 100 patients receiving ICI monotherapy at Seoul National University Bundang Hospital were reviewed, with additional genomic analyses using The Cancer Genome Atlas and an ICI-treated cohort from cBioPortal. Female patients with TP53 mutations showed prolonged median progression-free survival and higher PD-L1 expression, consistent with public dataset trends and immune-related gene and TMB enrichment.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-of-tp53-mutation-status-and-sex-with-clinical-outcome-in-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors-a-retrospective-cohort-study/335755/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-of-tp53-mutation-status-and-sex-with-clinical-outcome-in-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors-a-retrospective-cohort-study/335755.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study purpose regarding TP53 mutations and sex in NSCLC treated with ICI?","Question",{"text":112,"@type":113},"The study tested whether TP53 mutations could function as sex-dependent genomic biomarkers for immune checkpoint inhibitor response in non-small cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and datasets analyzed?",{"text":117,"@type":113},"Researchers retrospectively reviewed clinical data of 100 metastatic NSCLC patients treated with ICI monotherapy and also analyzed genomic and clinical datasets from The Cancer Genome Atlas and an ICI-treated lung cancer cohort in cBioPortal.",{"name":119,"@type":110,"acceptedAnswer":120},"What key outcomes were observed for females with TP53 mutations?",{"text":121,"@type":113},"In the SNUBH cohort, females with TP53 mutations had significantly prolonged median progression-free survival versus wild-type, and PD-L1 high expression was enriched in this group.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the findings suggest for future research?",{"text":125,"@type":113},"Results indicate that TP53 mutations may be linked to sex disparities in ICI response, supporting further studies to clarify the underlying role of TP53 in treatment outcomes.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335755,1790129969,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","pISSN 1598-2998, eISSN 2005-9256  \n\n| [https://doi.org/10.4143/crt.2024.046](https://doi.org/10.4143/crt.2024.046) Cancer Res Treat. 2025;57(1):70-82\u003Cbr>\u003Cbr>Original Article\u003Cbr>Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors:\u003Cbr>A Retrospective Cohort Study\u003Cbr>Songji Choi1 , Se Hyun Kim1 , Sejoon Lee2 , Jeongmin Seo1 , Minsu Kang1 , Eun Hee Jung1 , Sang-A Kim1 , Koung Jin Suh1 , Ji Yun Lee1 , Ji-Won Kim1 , Jin Won Kim1 , Jeong-Ok Lee1 , Yu Jung Kim1 , Keun-WookLee1 , Jee Hyun Kim1,2 , Soo-Mee Bang1 , Jong Seok Lee1 1Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, 2Precision Medicine Center, Seoul National University Bundang Hospital, Seongnam, Korea |  |\n| --- | --- |\n| Purpose Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) inpatients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.\u003Cbr>Materials and Methods Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.\u003Cbr>Results In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p \u003C 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.\u003Cbr>Conclusion Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.\u003Cbr>Key words TP53 mutation, Sex disparity, Lung neoplasms, Immune checkpoint inhibitors, PD-L1 |  |\n| Introduction | mutation burden (TMB), immune signature, and mismatch repair are potential predictive factors of the benefits of ICI |\n| Lung cancer is one of the leading causes of cancer-related mortality worldwide, with a 5-year survival rate of only | treatment [6] . To date, microsatellite instability status and strong PD-L1 expression in tumor cells are the only clinically |\n| 19% . Most patients with lung cancer (85%) suffer from | recommended predictive biomarkers of ICI efficacy, as deter- |\n| non–small cell lung cancer (NSCLC) [1,2] . Immunotherapy, | mined by polymerase chain reaction and immunohistochem- |\n| especially immune checkpoint inhibitor (ICI), has signifi- | istry, respectively [5,7]. Among the various known potential |\n| cantly improved clinical outcomes in patients with advanced | factors, specific genomic alterations can improve the efficacy |\n| NSCLC, achieving an outstanding duration of disease control | of immunotherapy. An in-depth understanding of genetic |\n| compared to standard cytotoxic chemotherapy approaches [3-5] . | alterations and molecular profiling based on next-generation sequencing (NGS) has dramatically changed the landscape |\n| Currently, only a small group (up to 20%) of patients achi- | of precision therapy","cbCaiq1zimp1vik1","https://ap.wps.com/l/cbCaiq1zimp1vik1","pdf",1748498,13,"English","# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What was the study purpose regarding TP53 mutations and sex in NSCLC treated with ICI?\",\"answer\":\"The study tested whether TP53 mutations could function as sex-dependent genomic biomarkers for immune checkpoint inhibitor response in non-small cell lung cancer.\"},{\"question\":\"How were patients and datasets analyzed?\",\"answer\":\"Researchers retrospectively reviewed clinical data of 100 metastatic NSCLC patients treated with ICI monotherapy and also analyzed genomic and clinical datasets from The Cancer Genome Atlas and an ICI-treated lung cancer cohort in cBioPortal.\"},{\"question\":\"What key outcomes were observed for females with TP53 mutations?\",\"answer\":\"In the SNUBH cohort, females with TP53 mutations had significantly prolonged median progression-free survival versus wild-type, and PD-L1 high expression was enriched in this group.\"},{\"question\":\"What do the findings suggest for future research?\",\"answer\":\"Results indicate that TP53 mutations may be linked to sex disparities in ICI response, supporting further studies to clarify the underlying role of TP53 in treatment outcomes.\"}]","Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors - A Retrospective Cohort Study | PDF",1790012210,33]